A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
Public ClinicalTrials.gov record NCT05119335. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1/2 Open Label Dose-escalation and Expansion Trial of NKT2152 an Orally Administered HIF2α Inhibitor to Investigate Safety Pharmacokinetics Pharmacodynamics and Clinical Activity in Patients With Advanced Clear Cell Renal Cell Carcinoma
Study identification
- NCT ID
- NCT05119335
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- NiKang Therapeutics, Inc.
- Industry
- Enrollment
- 120 participants
Conditions and interventions
Conditions
- Advanced Renal Cell Carcinoma
- Clear Cell
- Clear Cell Renal Cell Carcinoma
- HIF2α Inhibitor
- Hypoxia
- Hypoxia Inducible Factor (HIF)
- Hypoxia Inducible Factor 2 Alpha (HIF-2 Alpha)
- Hypoxia Inducible Factor 2α (HIF-2α)
- Kidney Cancer
- Kidney Neoplasms
- Metastatic Renal Cell Carcinoma
- Recurrent Renal Cell Carcinoma
- Refractory Renal Cell Carcinoma
- Renal Cancer
- Renal Cell Carcinoma
- Renal Neoplasms
- ccRCC
Interventions
- Oral NKT2152 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 25, 2021
- Primary completion
- Aug 21, 2025
- Completion
- Sep 29, 2025
- Last update posted
- Nov 11, 2025
2021 – 2025
United States locations
- U.S. sites
- 13
- U.S. states
- 13
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| HonorHealth | Scottsdale | Arizona | 85258 | — |
| UCLA | Los Angeles | California | 90095 | — |
| Sarah Cannon Research Institute | Denver | Colorado | 80218 | — |
| Emory University | Atlanta | Georgia | 30322 | — |
| Indiana University Simon Comprehensive Cancer Center | Indianapolis | Indiana | 46202 | — |
| University of Iowa | Iowa City | Iowa | 52242 | — |
| National Cancer Institute | Bethesda | Maryland | 20892-9760 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Nebraska Cancer Specialists | Omaha | Nebraska | 68130 | — |
| University of Oklahoma | Oklahoma City | Oklahoma | 73117 | — |
| Oregon Health and Science University | Portland | Oregon | 97239 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05119335, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 11, 2025 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05119335 live on ClinicalTrials.gov.